Development and Optimization of PEGylated Nanoliposomes Loaded with Amiodarone Using Microfluidic Technique for Enhanced Cardiovascular Drug Delivery

Authors

  • Lu Fan * Beijing Technology and Business University, China.

https://doi.org/10.48313/bic.vi.47

Abstract

Amiodarone is an effective Class III antiarrhythmic drug, but its clinical application is limited due to low solubility, irregular bioavailability, and severe side effects such as pulmonary toxicity. In this study, PEGylated nanoliposomes loaded with amiodarone were prepared and optimized using the microfluidic method to overcome these limitations. Six formulations with varying molar ratios of HEPC:Cholesterol: DSPE-PEG2000 were evaluated. The optimal formulation (55:40:5) exhibited the highest Encapsulation Efficiency (EE%) (94.8±1.6%), excellent colloidal stability (minimal change in size from 92 to 95 nm over 3 months), appropriate zeta potential (-8.2±1.3 mV) due to PEG shielding, and uniform spherical morphology with sizes of 70–159 nm (mean ≈105 nm). Scanning Electron Microscopy (SEM) images confirmed the absence of aggregation and smooth particle surfaces. These characteristics highlight the system's potential for prolonged blood circulation, passive targeting to damaged cardiac tissue, and reduction of amiodarone side effects. The results indicate that the optimized formulation offers a promising advanced drug delivery platform for safer and more effective treatment of cardiac arrhythmias.

Keywords:

Amiodarone, PEGylated nanoliposomes, Microfluidic, Encapsulation efficiency, Colloidal stability, Cardiovascular drug delivery

References

  1. [1] Jacob, G. S., & Shailubhai, K. (2014). Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders. Google patents, 8, 451–637. https://patents.google.com/patent/WO2010009319A2/en
  2. [2] Vangoitsenhoven, R., Corbeels, K., Mathieu, C., Overbergh, L., & der Schueren, B. (2016). The inseverable link between obesity and glucose intolerance and how to break it. Diabetes res. metab, 2, 1–22.
  3. [3] Diamanti-Kandarakis, E., Christakou, C. D., Kandaraki, E., & Economou, F. N. (2010). Metformin: An old medication of new fashion: Evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. European journal of endocrinology, 162(2), 193–212. https://doi.org/10.1530/EJE-09-0733
  4. [4] Paganoni, R. C., Pluenneke, J. C., Mohamed, A. M., Hayes, C. H., Freiberger-O’Keefe, C. E., & Chan, P. S. (2025). Early amiodarone or lidocaine administration during in-hospital cardiac arrest caused by shockable rhythms. Resuscitation plus, 22, 100872. https://doi.org/10.1016/j.resplu.2025.100872
  5. [5] Smida, T., Crowe, R., Price, B. S., Scheidler, J., Martin, P. S., Shukis, M., & Bardes, J. (2025). A retrospective ‘target trial emulation’ comparing amiodarone and lidocaine for adult out-of-hospital cardiac arrest resuscitation. Resuscitation, 208, 110515. https://doi.org/10.1016/j.resuscitation.2025.110515
  6. [6] Sharma, A., & Sharma, U. S. (1997). Liposomes in drug delivery: Progress and limitations. International journal of pharmaceutics, 154(2), 123–140. https://doi.org/10.1016/S0378-5173(97)00135-X
  7. [7] Thakur, N., Abhilash, C., Vivek, K., Nitan, B., & Neeraj, B. (2016). Liposome: Emerging trends in transdermal drug delivery. World journal of pharmacy and pharmaceutical sciences, 5, 511–525. https://www.wjpps.com/wjpps_controller/abstract_id/5063
  8. [8] Yusaf, R., Nawaz, R., Hayat, S., Khursheed, A., Zafar, N., Ahmad, A., … ., & Majeed, I. (2014). Structural components of liposomes and characterization tools. American journal of pharm research, 4(08).
  9. [9] Pulak Das, P. Das, Santosh Joshi, S. J., Jayashree Rout, J. R., & Upreti, D. K. (2013). Lichen diversity for environmental stress study: application of index of atmospheric purity (IAP) and mapping around a paper mill in Barak Valley, Assam, northeast India.
  10. [10] Wilczewska, A. Z., Niemirowicz, K., Markiewicz, K. H., & Car, H. (2012). Nanoparticles as drug delivery systems. Pharmacological reports, 64(5), 1020–1037. https://doi.org/10.1016/S1734-1140(12)70901-5
  11. [11] Patel, A., Ray, S., & Thakur, R. S. (2006). Invitro evaluation and optimization of controlled release floating drug delivery system of metformin hydrochloride. DARU journal of pharmaceutical sciences, 14(2), 57–64. https://www.researchgate.net/publication/281392173
  12. [12] Dogra, S. (2011). A chitosan-polymer hydrogel bead system for a metformin hydrochloride controlled release oral dosage form [Thesis]. https://www.proquest.com/openview/a11b28655d5f0365efbfc5c7a5ab5c41/1?pq-origsite=gscholar&cbl=18750
  13. [13] Banerjee, P., Deb, J., Roy, A., Ghosh, A., & Chakraborty, P. (2012). Fabrication and development of pectin microsphere of metformin hydrochloride. International scholarly research notices, 2012(1), 1-7. https://doi.org/10.5402/2012/230621
  14. [14] Pradeep, A. R., Nagpal, K., Karvekar, S., Patnaik, K., Naik, S. B., & Guruprasad, C. N. (2015). Platelet-rich fibrin with 1% metformin for the treatment of intrabony defects in chronic periodontitis: A randomized controlled clinical trial. Journal of periodontology, 86(6), 729–737. https://doi.org/10.1902/jop.2015.140646
  15. [15] Marzban, A., Akbarzadeh, A., Ardestani, M. S., Ardestani, F., & Akbari, M. (2018). Synthesis of nano-niosomal deferoxamine and evaluation of its functional characteristics to apply as an iron-chelating agent. The canadian journal of chemical engineering, 96(1), 107–112. https://doi.org/10.1002/cjce.23048
  16. [16] Xia, F., Hu, D., Jin, H., Zhao, Y., & Liang, J. (2012). Preparation of lutein proliposomes by supercritical anti-solvent technique. Food hydrocolloids, 26(2), 456–463. https://doi.org/10.1016/j.foodhyd.2010.11.014
  17. [17] Motallebi Tala Tapeh, S., Baei, M. S., & Keshel, S. H. (2021). Synthesis of thermogel modified with biomaterials as carrier for hUSSCs differentiation into cardiac cells: Physicomechanical and biological assessment. Materials science and engineering: c, 119, 111517. https://doi.org/10.1016/j.msec.2020.111517
  18. [18] De Lima, J. G., & Nóbrega, L. H. C. (2013). Oral therapies for type 2 diabetes. In Endocrinology and diabetes: A problem-oriented approach (pp. 375–384). Springer. https://doi.org/10.1007/978-1-4614-8684-8_29
  19. [19] Sharma, H. K., Lahkar, S., & Nath, L. K. (2013). Formulation and in vitro evaluation of metformin hydrochloride loaded microspheres prepared with polysaccharide extracted from natural sources. Acta pharmaceutica, 63(2), 209–222. https://doi.org/10.2478/acph-2013-0019
  20. [20] Niknejad, K., Sharifzadeh Baei, M., & Motallebi Tala Tapeh, S. (2018). Synthesis of metformin hydrochloride nanoliposomes: Evaluation of physicochemical characteristics and release kinetics. International journal of nano dimension, 9(3), 298–313. https://dorl.net/dor/20.1001.1.20088868.2018.9.3.9.7
  21. [21] Basak, S., & Das, T. K. (2025). Liposome-based drug delivery systems: From laboratory research to industrial production—instruments and challenges. ChemEngineering, 9(3), 1-20. https://doi.org/10.3390/chemengineering9030056

Downloads

Published

2025-09-27

Issue

Vol. 2 No. 3 (2025): Biocompounds

Section

Articles

How to Cite

Fan, L. . (2025). Development and Optimization of PEGylated Nanoliposomes Loaded with Amiodarone Using Microfluidic Technique for Enhanced Cardiovascular Drug Delivery. Biocompounds, 2(3), 196-202. https://doi.org/10.48313/bic.vi.47

Similar Articles

You may also start an advanced similarity search for this article.